ArticleSurgical endoscopy2025
Postoperative outcomes in transplant patients undergoing ventral hernia repair.
Article in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransplant patients undergoing ventral hernia repair are classified as Ventral Hernia Working Group 2, indicating higher risk for adverse outcomes. This study assessed perioperative outcomes in transplant patients undergoing ventral hernia repair compared to a case-matched cohort of non-transplant patients.
methodsA retrospective review was conducted using a prospectively maintained database of patients who underwent ventral hernia repair between January 2018 and March 2024. Inclusion criteria included prior liver, kidney, heart, lung, or islet cell transplant patients. A 1:1 case-match was performed. Primary outcomes included 30-day complications and hernia recurrence at a mean follow-up of 13 months.
resultsIn total, 253 patients were included. Thirty-two transplant patients were matched to 32 patients in the control group. No difference was observed in 30-day postoperative complications including SSOs (p = 0.13) and SSIs (p = 0.16). The hernia recurrence rate was 12.1 and 3.0% in the transplant and non-transplant cohorts, respectively (p = 0.16). In the transplant cohort alone, hernia recurrence was higher in patients receiving absorbable mesh compared to non-absorbable mesh (23.1% vs. 2.9%, p = 0.06), non-midline versus midline hernias (25.0% vs. 0.0%, p = 0.02), and patients on sirolimus or other immunosuppression medications versus tacrolimus (40.0% vs. 15.4% vs. 0.0%, p = 0.01). Two of the recurrences were bridged repairs.
conclusionsIn our study we did not observe increased risk of adverse outcomes in midline hernia repairs in transplant patients. However, non-midline ventral hernias significantly impact ventral hernia outcomes in transplant patients. In a case-matched cohort, there was no increased rates of SSI or SSO in transplant patients compared to nontransplant patients, but hernia recurrence rates were higher in the transplant cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.